ACS Medicinal Chemistry Letters · 2017 · 34 citations · 24 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryProdrug DesignBioactive Small MoleculesEnzyme InhibitionMicrotubule-associated ProteinsMicrotubule-targeting AgentsApoptotic Cell Death RegulationBiological Evaluation ReportCell Viability AssaysLight ExposureMicrotubule-targeted ProdrugsMolecular TargetingTubulin Polymerization InhibitorsUv Light Applications
Photoremovable protecting groups added to bioactive molecules provide spatial and temporal control of the biological effects. We present synthesis and characterization of the first photoactivatable small-molecule tubulin inhibitor. By blocking the pharmacophoric OH group on compound 1 with photoremovable 4,5-dimethoxy-2-nitrobenzyl moiety we developed the photocaged prodrug 2 that had no effect in biological assays. Short UV light exposure of the derivative 2 or UV-irradiation of cells treated with 2 resulted in fast and potent inhibition of tubulin polymerization, attenuation of cell viability, and apoptotic cell death, implicating release of the parent active compound. This study validates for the first time the photoactivatable prodrug concept in the field of small molecule tubulin inhibitors. The caged derivative 2 represents a novel tool in antitubulin approaches.
24
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting
Yayuan Liu, Rui Ran, Jiantao Chen et al. · Biomaterials · 2014 · 245 citations
Pharmacy, Oncology, Pharmaceutics +12
EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme
Bryan W. Day, Brett W. Stringer, Fares Al‐Ejeh et al. · Cancer Cell · 2013 · 215 citations · Full text
Medicine, Cancer Biology, Oncology +16